Issue 7, 2016
From the journal:

MedChemComm

Correction: Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells

Barbara Cortese,ab   Stefania D'Amone,a   Giuseppe Gigliacd  and  Ilaria Elena Palamà*a  

* Corresponding authors

a Institute Nanoscience CNR (NNL, CNR-NANO), via Arnesano, Lecce, Italy
E-mail: ilariaelena.palama@nano.cnr.it

b Department of Physics, University Sapienza, P. le A. Moro 5, Rome, Italy

c Dept. Matematica e Fisica ‘Ennio De Giorgi’, University of Salento, via Monteroni, Lecce, Italy

d Italian Institute of Technology (IIT) – Center for Biomolecular Nanotechnologies, via Barsanti, Arnesano, Italy

Abstract

Correction for ‘Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells’ by Barbara Cortese et al., Med. Chem. Commun, 2015, 6, 212–221.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/C6MD90031C
Article type
Correction
Submitted
16 Jun 2016
Accepted
16 Jun 2016
First published
24 Jun 2016
This article is Open Access
Creative Commons BY license

Med. Chem. Commun., 2016,7, 1450-1450

Permissions

Request permissions

Correction: Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells

B. Cortese, S. D'Amone, G. Gigli and I. E. Palamà, Med. Chem. Commun., 2016, 7, 1450 DOI: 10.1039/C6MD90031C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements